Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

• Navitoclax (BCL-XL/BCL-2 inhibitor)
• Pelabresib (BET inhibitor)
• Imetelstat (telomerase inhibitor)
• Luspatercept (erythroid maturation agent)
• Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.